Previous 10 | Next 10 |
CryoPort Inc. (CYRX) is expected to report $-0.31 for Q3 2023
Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition PR Newswire Strategic Acquisition Strengthens Condition Monitoring Systems and Logistics Management Capabilities for the Biopharmaceutical Industry Throughout Cryoport's Family of...
Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 PR Newswire NASHVILLE, Tenn. , Oct. 25, 2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and serv...
2023-10-12 09:06:35 ET More on CryoPort Cryoport to establish first U.K. logistics center Morgan Stanley starts Cryoport at equal weight, cites attractive fundamentals For further details see: Cryoport inks new multi-year supply chain solutions agreement with Mon...
Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF PR Newswire NASHVILLE, Tenn. , Oct. 12, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and se...
2023-10-10 12:39:59 ET More on CryoPort Cryoport: Great Potential That Management Continues To Fail To Actualize Cryoport, Inc. (CYRX) Q2 2023 Earnings Call Transcript Cryoport: Revising To Hold After Major Changes To Forecasts, Sentiment Morgan Stanley start...
Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies PR Newswire Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion ...
Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies PR Newswire Partnership will provide access to standardized and optimized apheresis collection, cryopreservation and bioprocessing processes throughout the U.S. and ...
2023-10-03 09:39:55 ET Summary Cryoport has experienced a decline in revenue and worsening bottom line results over the past year. The company's stock has fallen 30.6% since May and 64.2% since July 2022. Despite potential in the life sciences market, Cryoport needs to show pr...
Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award PR Newswire Company Named "Best Cell & Gene Therapy Supplier – Cryogenic Storage" NA...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities ...
Cryoport Reports First Quarter 2024 Financial Results PR Newswire Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...